Answers are grounded in this paper and cite their sources.
The 2026 American Transplant Congress, jointly organized by the American Society of Transplant Surgeons and the American Society of Transplantation, highlighted the expanding role of machine perfusion (MP) in broadening the donor pool across liver, kidney, lung, heart, and vascularized composite allograft transplantation. Of 106 relevant abstracts identified, 39 with the greatest clinical and translational relevance were selected for discussion. Across organ systems, normothermic and hypothermic MP facilitated utilization of higher-risk grafts, including donation-after-circulatory-death, steatotic, and extended-criteria organs, with early outcomes comparable or superior to static cold storage. Normothermic regional perfusion emerged as a complementary preconditioning strategy, particularly in reducing biliary complications after liver transplantation and delayed graft function after kidney transplantation. Novel biomarkers, including perfusate flavin mononucleotide, and integrated biochemical, physiologic, and histologic panels showed promise for real-time graft viability assessment. Emerging approaches, including 7-day liver preservation, ischemia-free liver transplantation, gaseous cardiac perfusion, and ex situ modeling of T-cell-mediated rejection, further suggest that MP is evolving into a therapeutic and investigative platform. Important limitations include variable benefits across recipient risk profiles, cardiac size-matching constraints, and disparities in access to normothermic liver perfusion. Multicenter validation, equitable access, and organ- and risk-specific strategies will be essential to realize the full potential of MP in transplantation.
No takes yet. Share an insight, caveat, or question.
White et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: